ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
2.760
+0.030 (1.10%)
At close: Aug 5, 2025, 4:00 PM
2.670
-0.090 (-3.26%)
Pre-market: Aug 6, 2025, 5:29 AM EDT
ADC Therapeutics Employees
As of December 31, 2024, ADC Therapeutics had 265 total employees, including 263 full-time and 2 part-time employees. The number of employees decreased by 9 or -3.28% compared to the previous year.
Employees
265
Change (1Y)
-9
Growth (1Y)
-3.28%
Revenue / Employee
$286,102
Profits / Employee
-$565,442
Market Cap
309.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 265 | -9 | -3.28% |
| Dec 31, 2023 | 274 | -43 | -13.56% |
| Dec 31, 2022 | 317 | 5 | 1.60% |
| Dec 31, 2021 | 312 | 104 | 50.00% |
| Dec 31, 2020 | 208 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADCT News
- 15 hours ago - ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - PRNewsWire
- 4 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 5 weeks ago - ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - PRNewsWire
- 7 weeks ago - ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) - PRNewsWire
- 7 weeks ago - ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 - PRNewsWire
- 7 weeks ago - ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - PRNewsWire
- 2 months ago - ADC Therapeutics to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript - Seeking Alpha